[11C]Mirtazapine binding in depressed antidepressant nonresponders studied by PET neuroimaging.
BACKGROUND
Lack of benefit from antidepressant drug therapy is a major source of human suffering, affecting at least 25% of people with major depressive disorder. We want to know whether nonresponse to antidepressants can be linked to aberrant neuroreceptor binding.


OBJECTIVE
This study aims to assess the antidepressant binding in brain regions of depressed nonresponders compared with healthy controls.


METHODS
Healthy volunteers and depressed subjects who had failed to benefit from at least 2 antidepressant treatments were recruited by newspaper advertisements. All subjects had received no antidepressant medication for at least 2 months before positron emission tomography (PET) that was carried out with [11C]mirtazapine. Kinetic parameters of [11C]mirtazapine were determined from PET data in selected brain regions by the simplified reference tissue model.


RESULTS
Binding potentials of [11C]mirtazapine in cerebral cortical regions were lower in depressed nonresponders than in healthy controls. Removal rates of [11C]mirtazapine were higher in diencephalic regions of depressed nonresponders than in healthy controls.


CONCLUSIONS
PET neuroimaging with [11C]mirtazapine showed aberrant neuroreceptor binding in brain regions of depressed subjects who had failed to benefit from treatment with antidepressant drugs.
Smith
Donald F
DF
Center for Psychiatric Research, Psychiatric Hospital of Aarhus University, Risskov, 8240, Denmark. dfsmithdfsmith@gmail.com
Stork
Bo S
BS
Wegener
Gregers
G
Ashkanian
Mahmoud
M
Jakobsen
Steen
S
Bender
Dirk
D
Audrain
Hélène
H
Vase
Karina H
KH
Hansen
Søren B
SB
Videbech
Poul
P
Rosenberg
Raben
R
D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D002250:Carbon Radioisotopes; D003865:Major Depressive Disorder / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D049268:Positron-Emission Tomography; D011485:Protein Binding
D000929:Antidepressive Agents, Tricyclic; D002250:Carbon Radioisotopes; D008803:Mianserin; D000078785:Mirtazapine